| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,1
* Department of Cellular and Molecular Medicine and Centre for Neuromuscular Disease, Faculty of Medicine,
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa; and
Ottawa Health Research Institute, Molecular Medicine Program, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
1Correspondence: Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada K1H 8M5. E-mail: jasmin{at}uottawa.ca
Although the molecular defect causing Duchenne/Becker muscular dystrophy (DMD/BMD) was identified nearly 20 years ago, the development of effective therapeutic strategies has nonetheless remained a daunting challenge. Over the years, a variety of different approaches have been explored in an effort to compensate for the lack of the DMD gene product called dystrophin. This review not only presents some of the most promising molecular, cellular, and pharmacological strategies but also highlights some issues that need to be addressed before considering their implementation. Specifically, we describe current strategies being developed to exogenously deliver healthy copies of the dystrophin gene to dystrophic muscles. We present the findings of several studies that have focused on repairing the mutant dystrophin gene using various approaches. We include a discussion of cell-based therapies that capitalize on the use of myoblast or stem cell transfer. Finally, we summarize the results of several studies that may eventually lead to the development of appropriate drug-based therapies. In this context, we review our current knowledge of the mechanisms regulating expression of utrophin, the autosomal homologue of dystrophin. Given the complexity associated with the dystrophic phenotype, it appears likely that a combinatorial approach involving different therapeutic strategies will be necessary for the appropriate management and eventual treatment of this devastating neuromuscular disease.—Chakkalakal, J. V., Thompson, J., Parks, R. J. Jasmin, B. J. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies.
Key Words: DMD • skeletal muscle • molecular therapy • muscle cell survival • dystrophin
This article has been cited by other articles:
|
|
 |
|
  C. L. Mendias, K. I. Bakhurin, and J. A. Faulkner Tendons of myostatin-deficient mice are small, brittle, and hypocellular PNAS, January 8, 2008; 105(1): 388 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Daftary, M. Crisanti, M. Kalra, B. Wong, and R. Amin Effect of Long-term Steroids on Cough Efficiency and Respiratory Muscle Strength in Patients With Duchenne Muscular Dystrophy Pediatrics, February 1, 2007; 119(2): e320 - e324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brunelli, C. Sciorati, G. D'Antona, A. Innocenzi, D. Covarello, B. G. Galvez, C. Perrotta, A. Monopoli, F. Sanvito, R. Bottinelli, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy PNAS, January 2, 2007; 104(1): 264 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, E. Kimura, R. Ng, B. M. Fall, L. Meuse, M. Reyes, J. A. Faulkner, and J. S. Chamberlain A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy Hum. Mol. Genet., May 15, 2006; 15(10): 1610 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Miura, J. Thompson, J. V. Chakkalakal, M. Holcik, and B. J. Jasmin The Utrophin A 5'-Untranslated Region Confers Internal Ribosome Entry Site-mediated Translational Control during Regeneration of Skeletal Muscle Fibers J. Biol. Chem., September 23, 2005; 280(38): 32997 - 33005. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
